Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06026332 · ClinicalTrials.gov registry record
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
A clinical trial, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- 202
- Enrollment target
NCT06026332 is a clinical trial that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 202 participants.
The verdict
NCT06026332 was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- 202 participants
- Enrollment target
Study Summary
Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting
Interventions
- DRUG ADSTILADRIN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2026-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06026332
The ClinicalTrials.gov registry entry for NCT06026332 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADSTILADRIN is the first listed.
NCT06026332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06026332 about?
NCT06026332 is a clinical study titled "ADSTILADRIN Early Utilization and Outcomes in the Real World Setting". Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting
What is the current status of trial NCT06026332?
This trial is currently terminated. The enrollment target is 202 participants. The study started on 2023-09-15. Estimated completion is 2026-01-15.
What interventions are being tested in trial NCT06026332?
The interventions under investigation include: ADSTILADRIN (DRUG).
Who is sponsoring clinical trial NCT06026332?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.